Background

Through the antioxidant and anti-inflammation pathways, melatonin is proposed as a safe and effective intervention in neurological diseases. This study aims to evaluate the effects of melatonin supplementation on the neurobehavioral and clinical outcomes in animal models of multiple sclerosis (MS).

Methods

This study was conducted following the PRISMA statement. Animal studies that reported the effects of melatonin in preclinical MS models, including the experimental autoimmune encephalomyelitis (EAE) and cuprizone model for demyelination are included in this study. A systematic search in PubMed, Web of Science, Embase, and Scopus up was conducted in April 2023. The collaborative Approach to Meta-Analysis and Review of Animal Experimental Studies (CAMARADES) critical appraisal tool was used for the quality assessment of the studies and the quantitative synthetizes were conducted using the comprehensive meta-analysis software.

Results

Out of 542 studies, finally 21 studies, including 14 studies in the EAE model and 7 studies of the toxic demyelination method with cuprizone were included. The route of administration was intraperitoneal in 18 studies, oral in 2 studies, and subcutaneous in 1 study. The quantitative synthesis of the EAE clinical severity scale was associated with significant differences (standardized mean difference [SDM]: − 2.52; − 3.61 to − 1.42; p value < 0.01). In subgroup analyses, the difference was statistically significant in the mouse subgroup (SMD: − 2.60; − 3.74 to − 1.46; p value < 0.01).

Discussion

This study encountered that melatonin may be associated with improved behavioral and cognitive outcomes of preclinical models of MS with acceptable safety profiles.

Funding

The research was supported by the Student Research Committee, Tabriz University of Medical Sciences (grant number: 71005).

中文翻译：

---

褪黑激素补充剂对多发性硬化症啮齿动物模型神经行为结果和临床严重程度的影响；系统评价和荟萃分析

背景

通过抗氧化和抗炎途径，褪黑激素被认为是神经系统疾病的安全有效的干预措施。本研究旨在评估补充褪黑激素对多发性硬化症 (MS) 动物模型神经行为和临床结果的影响。

方法

这项研究是根据 PRISMA 声明进行的。本研究纳入了动物研究，报告了褪黑激素对临床前 MS 模型的影响，包括实验性自身免疫性脑脊髓炎 (EAE) 和铜宗脱髓鞘模型。2023 年 4 月在 PubMed、Web of Science、Embase 和 Scopus up 中进行了系统检索。使用协作方法荟萃分析和动物实验研究审查 (CAMARADES) 关键评估工具对研究和结果进行质量评估。使用综合荟萃分析软件进行定量合成。

结果

在 542 项研究中，最终纳入了 21 项研究，其中包括 14 项 EAE 模型研究和 7 项铜宗毒性脱髓鞘方法研究。18 项研究的给药途径为腹膜内给药，2 项研究为口服给药，1 项研究为皮下给药。EAE 临床严重程度量表的定量综合与显着差异相关（标准化平均差 [S​​DM]：− 2.52；− 3.61 至 − 1.42；p值 < 0.01）。在亚组分析中，小鼠亚组的差异具有统计学意义（SMD：− 2.60；− 3.74 至− 1.46；p值< 0.01）。

讨论

这项研究发现，褪黑激素可能与改善多发性硬化症临床前模型的行为和认知结果相关，且安全性可接受。

资金

该研究得到了大不里士医科大学学生研究委员会的支持（拨款号：71005）。